Last checked at ValiRx Still Faces Going Out Of Business; Proposes New Share Plan
ValiRx Still Faces Going Out Of Business; Proposes New Share Plan
10 Mar 20 11:42
- Home
- Share Prices
- NEX Exchange Share Prices
- Share Chat
- FX
- News
- Blogs
- RNS
- Media
- Trading
- Finance Tools
- Members
Latest Share Chat
Valirx Share News (VAL)
VAL Share
Price
VAL Share
News
VAL Share
Chat
VAL Share
Trades8
VAL
Live RNS
VAL Share
Charts
VAL Level 2
Console
VAL Live
Share Price
VAL Broker
Ratings
VAL Directors
Deals
VAL Financial
Diary
VAL
Fundamentals
VAL Short
Positions
VAL
Media
VAL Information
Share Price Information for Valirx (VAL)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
0.0425
Bid:
0.035
Ask:
0.05
Change:
0.00
(0.00%)
Spread:
0.015 (42.86%)
Open:
0.043
High:
0.0425
Low:
0.0425
Yest. Close:
0.0425
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.10 Mar 20 11:42ValiRx Investors Seek Removal Of Directors Morris And Vainikka
ValiRx Investors Seek Removal Of Directors Morris And Vainikka
4 Mar 20 17:25ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation
ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation
17 Feb 20 12:48UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
10 Feb 20 16:00ValiRx signs letter of intent in a bid to fund VAL401
(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
14 Jan 20 14:50ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
14 Jan 20 11:08ValiRx Raises GBP200,000 To Progress Product Development
ValiRx Raises GBP200,000 To Progress Product Development
6 Jan 20 09:59ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
16 Dec 19 10:17ValiRx granted US patent for 'VAL201' compound
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.
28 Nov 19 16:13ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
28 Nov 19 15:57ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
14 Oct 19 13:44ValiRx Reports Narrowed Loss In First Half As Expenses Reduce
ValiRx Reports Narrowed Loss In First Half As Expenses Reduce
26 Sep 19 11:43ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
24 Sep 19 12:40ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints
(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and
10 Sep 19 13:45ValiRx Granted European Patent Allowance For VAL301 Compound
(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a
1 Aug 19 12:01